EA032401B1 - Бензилзамещенные индазолы в качестве ингибиторов bub1 - Google Patents

Бензилзамещенные индазолы в качестве ингибиторов bub1 Download PDF

Info

Publication number
EA032401B1
EA032401B1 EA201790649A EA201790649A EA032401B1 EA 032401 B1 EA032401 B1 EA 032401B1 EA 201790649 A EA201790649 A EA 201790649A EA 201790649 A EA201790649 A EA 201790649A EA 032401 B1 EA032401 B1 EA 032401B1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
tert
general formula
formula
group
Prior art date
Application number
EA201790649A
Other languages
English (en)
Russian (ru)
Other versions
EA201790649A1 (ru
Inventor
Анне Менгель
Ханс-Георг Лерхен
Манфред Мёвес
Томас Мюллер
Ларс Берфаккер
Марион Хитчкок
Арвед Клеве
Йоахим Кунке
Ханс Брим
Герхард Зимайстер
Вильхельм Боне
Амаури-Эрнесто Фернандес-Монтальван
Йенс Шрёдер
Урсула Мённинг
Зимон Хольтон
Original Assignee
Байер Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Фарма Акциенгезельшафт filed Critical Байер Фарма Акциенгезельшафт
Publication of EA201790649A1 publication Critical patent/EA201790649A1/ru
Publication of EA032401B1 publication Critical patent/EA032401B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EA201790649A 2014-09-19 2015-09-17 Бензилзамещенные индазолы в качестве ингибиторов bub1 EA032401B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14185604 2014-09-19
EP15176903 2015-07-15
PCT/EP2015/071340 WO2016042084A1 (en) 2014-09-19 2015-09-17 Benzyl substituted indazoles as bub1 inhibitors

Publications (2)

Publication Number Publication Date
EA201790649A1 EA201790649A1 (ru) 2017-09-29
EA032401B1 true EA032401B1 (ru) 2019-05-31

Family

ID=54140475

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790649A EA032401B1 (ru) 2014-09-19 2015-09-17 Бензилзамещенные индазолы в качестве ингибиторов bub1

Country Status (27)

Country Link
US (1) US10350206B2 (cg-RX-API-DMAC7.html)
EP (1) EP3194379A1 (cg-RX-API-DMAC7.html)
JP (1) JP6664385B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170049604A (cg-RX-API-DMAC7.html)
CN (1) CN107001331A (cg-RX-API-DMAC7.html)
AP (1) AP2017009803A0 (cg-RX-API-DMAC7.html)
AU (1) AU2015316796A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017005444A2 (cg-RX-API-DMAC7.html)
CA (1) CA2961589A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017000654A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017002532A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170100A (cg-RX-API-DMAC7.html)
CU (1) CU20170029A7 (cg-RX-API-DMAC7.html)
DO (1) DOP2017000078A (cg-RX-API-DMAC7.html)
EA (1) EA032401B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP17016797A (cg-RX-API-DMAC7.html)
IL (1) IL251071A0 (cg-RX-API-DMAC7.html)
MA (1) MA39484A (cg-RX-API-DMAC7.html)
MX (1) MX2017003664A (cg-RX-API-DMAC7.html)
NI (1) NI201700034A (cg-RX-API-DMAC7.html)
PE (1) PE20170697A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500509A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201702082VA (cg-RX-API-DMAC7.html)
TN (1) TN2017000092A1 (cg-RX-API-DMAC7.html)
TW (1) TW201615636A (cg-RX-API-DMAC7.html)
UY (1) UY36311A (cg-RX-API-DMAC7.html)
WO (1) WO2016042084A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
EP3495367B1 (en) 2012-06-13 2020-09-30 Incyte Holdings Corporation Substituted tricyclic compounds as fgfr inhibitors
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
CA2916116A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
ES2652305T3 (es) 2013-06-21 2018-02-01 Bayer Pharma Aktiengesellschaft Pirazoles heteroaril sustituidos
US9682974B2 (en) 2013-10-30 2017-06-20 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
SMT202400446T1 (it) 2014-02-06 2024-11-15 Nxera Pharma Uk Ltd Composti aza biciclici come agonisti del recettore muscarinico
TW201613886A (en) 2014-06-17 2016-04-16 Bayer Pharma AG 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
TN2017000092A1 (en) 2014-09-19 2018-07-04 Bayer Pharma AG Benzyl substituted indazoles as bub1 inhibitors.
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
CN108727340B (zh) 2017-04-11 2020-12-29 广东东阳光药业有限公司 氟取代的吲唑类化合物及其用途
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
CN112566912A (zh) 2018-05-04 2021-03-26 因赛特公司 Fgfr抑制剂的盐
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEAP202415945A (en) 2019-10-14 2024-04-25 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013050438A1 (en) * 2011-10-06 2013-04-11 Bayer Pharma Aktiengesellschaft Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5470862A (en) 1995-02-03 1995-11-28 Ohmeda Pharmaceutical Products Division Inc. Substituted pyrazolyl compounds and methods employing such compounds
CZ130999A3 (cs) 1996-10-14 1999-07-14 Bayer Aktiengesellschaft Heterocyklylmethyl-substituované deriváty pyrazolu, způsob jejich výroby, farmaceutické prostředky tyto látky obsahující a jejich použití pro výrobu léčiv
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
WO2003051833A2 (en) 2001-12-18 2003-06-26 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
US7166293B2 (en) 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
US20040132730A1 (en) 2002-09-10 2004-07-08 Jonathan Axon Inhibitors of TGFbeta
DE10244810A1 (de) 2002-09-26 2004-04-08 Bayer Ag Neue Morpholin-überbrückte Indazolderivate
US8748601B2 (en) 2003-04-11 2014-06-10 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
US20080242681A1 (en) 2004-01-22 2008-10-02 Altana Pharma Ag N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
AU2008253311A1 (en) 2007-05-18 2008-11-27 Bayer Schering Pharma Aktiengesellshaft Inhibitors of hypoxia inducible factor (HIF) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
US8354399B2 (en) 2008-12-18 2013-01-15 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
CN102666537A (zh) 2009-10-20 2012-09-12 艾格尔生物制药股份有限公司 治疗黄病毒科病毒感染的氮杂吲唑
CN102791707B (zh) 2009-11-27 2014-10-29 拜耳知识产权有限责任公司 {4,6-二氨基-2-[1-(2-氟苄基)-1h-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}甲基氨基甲酸甲酯的制备方法以及为了将其用作药用活性成分的纯化方法
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
RU2639876C2 (ru) 2010-03-30 2017-12-25 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
DK2588465T3 (en) 2010-06-30 2017-05-01 Ironwood Pharmaceuticals Inc SGC stimulators
WO2013092512A1 (en) 2011-12-21 2013-06-27 Bayer Intellectual Property Gmbh Substituted benzylpyrazoles
EP2797915B1 (en) 2011-12-27 2016-07-13 Ironwood Pharmaceuticals, Inc. 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure
HK1207861A1 (en) 2012-05-11 2016-02-12 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
US9487508B2 (en) 2012-09-19 2016-11-08 Ironwood Pharmaceuticals, Inc. SGC stimulators
US9738610B2 (en) 2012-09-24 2017-08-22 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
CA2907594A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
JP2016514718A (ja) 2013-03-21 2016-05-23 バイエル ファーマ アクチエンゲゼルシャフト ３−ヘテロアリール置換インダゾール類
HK1217324A1 (zh) 2013-03-21 2017-01-06 Bayer Pharma Aktiengesellschaft 二氨基杂芳基取代的吲唑
ES2652305T3 (es) 2013-06-21 2018-02-01 Bayer Pharma Aktiengesellschaft Pirazoles heteroaril sustituidos
CN105473570A (zh) 2013-06-21 2016-04-06 拜耳制药股份公司 二氨基杂芳基取代的吡唑
EP3010911A1 (en) 2013-06-21 2016-04-27 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
WO2014202583A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
CA2916116A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
US9682974B2 (en) 2013-10-30 2017-06-20 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
WO2016042080A1 (en) 2014-09-19 2016-03-24 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
CA2961586A1 (en) 2014-09-19 2016-03-24 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
WO2016042536A1 (en) 2014-09-19 2016-03-24 Glaxosmithkline Intellectual Property Development Limited Novel soluble guanylate cyclase activators and their use
TN2017000092A1 (en) 2014-09-19 2018-07-04 Bayer Pharma AG Benzyl substituted indazoles as bub1 inhibitors.
US20160082058A1 (en) 2014-09-19 2016-03-24 Nestec Sa Methods and formulations for treatment, reduction, and prevention of cancer in a companion animal and for the reduction of postprandial blood glucose in a companion animal
LT3194376T (lt) 2014-09-19 2019-02-25 Forma Therapeutics, Inc. Piridin-2(1h)-ono chinolinono dariniai, kaip mutantinės izocitratdehidrogenazės inhibitoriai
CN107148420A (zh) 2014-09-19 2017-09-08 拜耳制药股份公司 苄基取代的吲唑类化合物
WO2017148995A1 (en) 2016-03-04 2017-09-08 Bayer Pharma Aktiengesellschaft 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity
WO2017157992A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
WO2017157991A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013050438A1 (en) * 2011-10-06 2013-04-11 Bayer Pharma Aktiengesellschaft Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.

Also Published As

Publication number Publication date
CO2017002532A2 (es) 2017-07-11
US10350206B2 (en) 2019-07-16
JP6664385B2 (ja) 2020-03-13
KR20170049604A (ko) 2017-05-10
CU20170029A7 (es) 2017-08-08
JP2017530962A (ja) 2017-10-19
CR20170100A (es) 2017-04-24
PH12017500509A1 (en) 2017-08-30
CA2961589A1 (en) 2016-03-24
BR112017005444A2 (pt) 2018-04-24
UY36311A (es) 2016-04-29
CL2017000654A1 (es) 2017-12-11
MX2017003664A (es) 2017-07-13
CN107001331A (zh) 2017-08-01
SG11201702082VA (en) 2017-04-27
ECSP17016797A (es) 2017-05-31
WO2016042084A1 (en) 2016-03-24
EA201790649A1 (ru) 2017-09-29
PE20170697A1 (es) 2017-06-24
EP3194379A1 (en) 2017-07-26
US20170273980A1 (en) 2017-09-28
IL251071A0 (en) 2017-04-30
TN2017000092A1 (en) 2018-07-04
AU2015316796A1 (en) 2017-03-30
AP2017009803A0 (en) 2017-03-31
NI201700034A (es) 2017-06-16
MA39484A (fr) 2016-03-24
DOP2017000078A (es) 2017-06-30
TW201615636A (zh) 2016-05-01

Similar Documents

Publication Publication Date Title
EA032401B1 (ru) Бензилзамещенные индазолы в качестве ингибиторов bub1
JP7580393B2 (ja) Ｃｂｌ－ｂ阻害のための３－置換ピペリジン化合物、並びに癌ワクチン及び／又は腫瘍溶解性ウイルスと組み合わせたＣｂｌ－ｂ阻害剤の使用
JP7662519B2 (ja) 置換されたピラゾロピリミジン及び置換されたプリンならびにユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤としてのそれらの使用
KR102533477B1 (ko) 단백질 타이로신 포스파타아제 억제제 및 그의 사용 방법
DK3313850T3 (en) NEW AMINO ACID DERIVATIVES, PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP6871275B2 (ja) 新規アンモニウム誘導体、それを調製するためのプロセス及びそれを含有する医薬組成物
EA012869B1 (ru) Замещённые пиримидины, композиции на их основе и применение замещенных пиримидинов в качестве ингибиторов протеинкиназ
JP2016514718A (ja) ３−ヘテロアリール置換インダゾール類
RU2561130C2 (ru) НОВЫЕ ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОПИРИМИДО{1,2-a}ПИРИМИДИН-6-ОНА, ИХ ПОЛУЧЕНИЕ И ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
BR112021004774A2 (pt) compostos de triazol-pirimidina e seus usos
US20240300927A1 (en) Amides as cbl-b inhibitors
KR20150041787A (ko) 2,3-벤조디아제핀
UA111754C2 (uk) Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
EA028057B1 (ru) Производные аминопиримидина для применения в качестве модуляторов киназной активности
IL289933B1 (en) 6,7-dihydro-5h-pyrido[2,3-c]pyridazine derivatives and related compounds as bcl-xl protein inhibitors and pro-apoptotic agents for treating cancer
AU2014337314A1 (en) Compositions useful for treating disorders related to KIT
EA020151B1 (ru) Ингибиторы akt и фармацевтические составы, их содержащие
BR112015014752B1 (pt) Compostos e seus uso para modulação de cinase
ES2627428T3 (es) Nuevos derivados de 2,3-dihidro-1H-imidazo{1,2-a}pirimidin-5-ona, su preparación y su utilización farmacéutica
JP2021519785A (ja) 共有結合性メニン阻害剤としてのピペリジン化合物
EA025098B1 (ru) Имидазоламины в качестве модуляторов киназной активности
CN117500507A (zh) 作为新的sos1抑制剂的磷衍生物
EP3686197B1 (en) 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof
JP2017505319A (ja) Ｅｇｆｒ−ｔ７９０ｍキナーゼ阻害剤として置換されたピリミジニウム類化合物
EP3781560A1 (en) Pyrazo-tetrahydroisoquinoline derivatives as dopamine d1 receptor positive modulators

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY KZ RU